MFN Drug Pricing Savings: Projected $593 Billion in U.S. Healthcare Savings Over Ten Years

The MFN drug pricing savings under the Trump Administration’s voluntary framework total hundreds of billions of dollars. The policy has already secured agreements with 17 manufacturers and is projected to deliver $529 billion in U.S. savings over ten years from new drugs, plus an additional $64.3 billion from Medicaid MFN on existing drugs. These figures are based on Council of Economic Advisers modeling across commercial, Medicare, Medicaid, and direct-to-consumer markets.

Key Insights

• Prospective MFN links U.S. launch prices for new sole-source drugs and biologics to net prices in peer nations, an approach that generates the $529 billion savings estimate.
• Medicaid MFN requires manufacturers to match reference prices on existing products, producing $64.3 billion in combined federal and state savings.
• Direct-to-consumer discounts offered through TrumpRx.gov deliver immediate relief; uninsured GLP-1 users can save roughly $3,000 per year, while couples using fertility drugs can save more than $6,000 per live birth.
• The policy pairs lower U.S. prices with trade measures that raise foreign prices, protecting overall R&D revenue while shifting a greater share of payer contributions to other high-income countries.

Background Context

The United States pays roughly three times the net prices paid by peer countries, yet it still accounts for more than half of global pharmaceutical revenue. Research and development costs for a new drug range from $1 billion to $2.8 billion, with U.S. payers currently shouldering most of that burden.

The MFN reference price is set at the second-lowest net price among G-7 nations (excluding the U.S.), Denmark, and Switzerland, with prices adjusted for GDP per capita. Manufacturers report confidential net prices to CMS. The savings models apply this benchmark to FDA novel-drug cohorts from 2021–2025 and then project forward ten years, assuming 3 percent annual spending growth and 30 percent long-term price convergence.

Implications

For health economics researchers, the Most-Favored-Nation (MFN) drug pricing policy provides a live reference-pricing benchmark. Analysts can now examine how rebalanced payer contributions affect short-term budgets and long-term innovation, and assess whether the projected savings improve patient access without reducing global revenue for new therapies.

Learn more about the complete fiscal modeling in this detailed White House analysis.

FAQ

How does Medicaid MFN affect state budgets?
States are expected to realize $27.6 billion of the $64.3 billion total Medicaid savings over ten years through supplemental rebates.

Will MFN reduce future drug innovation?
The policy is designed to keep total manufacturer revenue stable by shifting a larger share of R&D costs to other high-income countries, while preserving the 17 voluntary manufacturer agreements already secured.

Do TrumpRx.gov prices count toward insurance deductibles?
Proposed rules would allow MFN-priced direct purchases to apply toward commercial deductibles and the Medicare Part D out-of-pocket cap.

Reference

White House. (2026). Savings from Most-Favored-Nation Drug Pricing Policy. https://www.whitehouse.gov/research/2026/05/savings-from-most-favored-nation-drug-pricing-policy/